G. Saturday

This study demonstrates limited MERS-CoV transmission via aerosol, fomite, and direct contact in a transgenic human DPP4 mouse model.

This study evaluates a bivalent Adenovirus-Vectored Vaccine in cynomolgus macaques against Sudan virus, finding it induces humoral responses but does not confer protection against lethal challenge.

This study compares SARS-CoV-2 replication in rhesus macaques after intranasal inoculation or aerosol exposure, finding differences in respiratory tract involvement.

This study shows that rectal and vaginal mpox virus inoculation in rats leads to more virus shedding and contact transmission compared to skin inoculation.

This study develops a VSV-based vaccine against Sudan virus and shows it protects macaques from lethal infection, highlighting the need for specific countermeasures against filoviruses.

This study identifies a monoclonal antibody, mAb92, that targets the Nipah virus fusion glycoprotein and provides complete protection in hamsters.

The combination of molnupiravir and nirmatrelvir inhibits SARS-CoV-2 replication and shedding more effectively than individual treatments in the rhesus macaque model.

This study shows a replicon RNA vaccine provides durable protection against SARS-CoV-2 in nonhuman primates even after neutralizing antibodies decline.

This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.

This study shows that SARS-CoV-2 infected mink develop severe respiratory disease with features similar to severe acute respiratory disease in humans.

ChAdOx1 NiV vaccination protects African green monkeys from lethal Nipah virus infection, preventing disease signs and viral replication.

This paper establishes a pigtailed macaque model for KFDV and AHFV that replicates human disease symptoms and viral tropism.

This study compares the pathogenicity of SARS-CoV-2 variants B.1.1.7 and B.1.351 in rhesus macaques, finding differences in clinical outcomes and immune responses.

This study shows that T cell depletion in rhesus macaques does not cause severe SARS-CoV-2 disease but delays viral clearance, and T cells are not essential for immunological memory or protection against re-infection.

This study shows that the ChAdOx1 nCoV-19 vaccine protects Syrian hamsters from SARS-CoV-2 B.1.1.7 and B.1.351 variants, preventing weight loss, lung lesions, and viral replication.

This study shows ZIKV NS5 inhibits mitophagy by blocking Ajuba's role in PINK1-Parkin signaling, leading to increased inflammation and viral spread.

This study shows intranasal ChAdOx1 nCoV-19 vaccination reduces SARS-CoV-2 shedding in animal models but not pneumonia protection.

The paper shows Syrian hamsters are highly susceptible to SARS-CoV-2, making them a suitable model for developing countermeasures against COVID-19.

This study shows hydroxychloroquine does not reduce SARS-CoV-2 replication or improve clinical outcomes in hamsters or macaques.

This study shows that the ChAdOx1 nCoV-19 vaccine reduces SARS-CoV-2 viral load and prevents pneumonia in rhesus macaques without causing immune-enhanced disease.

This study shows remdesivir reduces SARS-CoV-2 viral load and lung damage in rhesus macaques when administered early in infection.

A single dose of ChAdOx1 MERS vaccine protects rhesus macaques and mice against MERS-CoV infection and multiple strains.

This study shows that SARS-CoV-2 causes respiratory disease in rhesus macaques with symptoms similar to human cases, including prolonged viral shedding.